An interventional study of Drug-coated balloon (DCB) and Drug-eluting stent (DES) in ST-elevation Myocardial Infarction (STEMI), sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in ST Elevation Myocardial Infarction with a site in China — 41 open to participants now, 43 under way, 2 of them phase 3. ST Elevation Myocardial Infarction · China.
Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, this one is the 21st largest by planned enrollment of the 97 interventional ones that give a count, is one of 11 that started in 2025, is one of 51 with no phase, reaches primary completion later than 40 of the 42 other live ones, and was the 118th registered.
851 studies on the registry are indexed under ST Elevation Myocardial Infarction; 198 are open to participants now.
Browse ST Elevation Myocardial Infarction studies →41 of the 146 studies in ST Elevation Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:
Harbin Medical University · Sites in China
Ages 18–75
Renmin Hospital of Wuhan University · Sites in China
Ages 18–80
Beijing Sungen Biomedical Technology Co., Ltd · Sites in China
Ages 18–79
Chen Jing · Sites in China
Ages 18+
Novartis Pharmaceuticals · Sites in China, Argentina, Australia and 11 more countries
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 122 ST Elevation Myocardial Infarction studies recruiting now, 76 (62%) set no upper age limit and 20 (16%) stop at 75 or younger; 10 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 10 · Phase 3 11 · Phase 4 25
First in 2003; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,244 is above the median of 193 across 528 interventional studies indexed under ST Elevation Myocardial Infarction.
Median enrollment 320 across the 97 interventional studies, 737 across the 48 observational. Of the 39 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 146 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.
Second Affiliated Hospital, Zhejiang University, School of Medicine has 2 studies filed under ST Elevation Myocardial Infarction — fewer than ten, so there is no comparison to draw.
17 of the studies in ST Elevation Myocardial Infarction with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-02-11 |
| NCT06794801LanZhou UniversityEvaluating the Safety and Efficacy of Drug-Coated Autoperfusion Balloons Versus Conventional Drug-Coated Balloons Guided by IVUS-OCT Multimodal Imaging for Treating Acute Myocardial Infarction: OPERA-AMI Study | 2026-12 |
| NCT05967663RenJi HospitalFractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study) | 2026-12 |
| NCT06339021Shenyang Northern HospitalOCT or Angiography Guided De-escalation of DAPT | 2026-12-01 |
| NCT06548204Second Affiliated Hospital, Zhejiang University, School of MedicineEffect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial | 2026-12-30 |
Add all 17 to your calendar (.ics) → With an account.
Among the 146 studies in ST Elevation Myocardial Infarction with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Acute ST-segment elevation myocardial infarction (STEMI) is a life-threatening emergency requiring immediate intervention. The incidence of premature coronary artery disease (PCAD) is rising rapidly in China; its long-term prognosis remains poor and it frequently progresses to acute myocardial infarction, necessitating high-risk therapies such as primary percutaneous coronary intervention (PCI) or coronary artery bypass grafting, thereby imposing enormous economic and psychological burdens on patients and their families. Moreover, the cumulative 6-year rate of death or myocardial infarction after implantation of the latest-generation drug-eluting stents still reaches 15%, and management of stent failure is extremely challenging. Drug-coated balloon (DCB) angioplasty-representing the "leave-nothing-behind" paradigm-is a highly promising option in young subjects. Accumulating clinical evidence demonstrates that DCB provides favorable efficacy across a broad spectrum of lesions, including small-vessel and large-vessel de novo disease, bifurcation lesions, and in-stent restenosis. Nevertheless, high-quality data on the impact of DCB angioplasty in de novo large-vessel disease and in the setting of acute STEMI are still lacking.
Objectives of Study:
Compare the clinical outcomes of drug-coated balloon (DCB) and drug-eluting stent (DES) treatment in patients with ST-segment elevation myocardial infarction (STEMI).
Design of Study:
Investigator-Initiated,Open Label,Prospective,Multicenter,Randomized Clinical Trial.
Patients Selected: This study aims to STEMI patients who have successfully completed lesion pretreatment in multiple medical centers in China. Patients who meet the inclusion criteria and have no exclusion criteria will be randomly assigned 1:1 to the drug coated balloon group and drug eluting stent group, totaling 1244 cases (622 cases per group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
STEMI patients undergo revascularization using DCB
Device: Drug-coated balloon (DCB)
STEMI patients undergo revascularization using DES
Device: Drug-eluting stent (DES)
Drug-coated balloon treatment of target lesions in patients with STEMI undergoing percutaneous coronary intervention.
Drug-eluting stent treatment of target lesions in patients with STEMI undergoing percutaneous coronary intervention.
Incidence of patient-oriented composite endpoints (POCE) (Direct measurement and coronary angiography)
POCE including all-cause mortality, any stroke, any myocardial infarction (MI), and any revascularization, will be obtained through follow-up of subjects.
Time frame: 12 months
Incidence of patient-oriented composite endpoints (POCE) (Direct measurement and coronary angiography)
POCE including all-cause mortality, any stroke, any myocardial infarction (MI), and any revascularization, will be obtained through follow-up of subjects.
Time frame: 36 months, 60 months
Incidence of target vessel failure (Direct measurement and coronary angiography)
Target vessel failure (a composite of cardiac death, target-vessel MI, or target vessel revascularization) will be obtained through follow-up of subjects.
Time frame: 12 months
Incidence of all-cause mortality (Direct measurement)
All-cause mortality will be obtained through follow-up of subjects.
Time frame: 36 months, 60 months
Incidence of non-fatal MI (Direct measurement)
Non-fatal MI will be obtained through follow-up of subjects.
Time frame: 36 months, 60 months
Incidence of any revascularization (coronary angiography)
Any revascularization will be obtained through follow-up of subjects.
Time frame: 36 months, 60 months
Incidence of all-cause and cardiac death (Direct measurement)
All-cause and cardiac death will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
Incidence of any non-fatal MI without peri-procedural MI (Direct measurement)
Any non-fatal MI without peri-procedural MI will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
Incidence of any non-fatal MI with peri-procedural MI (Direct measurement)
Any non-fatal MI with peri-procedural MI will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
Incidence of any target vessel/lesion revascularization (Coronary angiography)
Any target vessel/lesion revascularization will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
Incidence of any non-target vessel/lesion revascularization (Coronary angiography)
Any non-target vessel/lesion revascularization will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
Incidence of any revascularization (ischemia-driven or all) (Coronary angiography)
Any revascularization (ischemia-driven or all) will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
Incidence of non-fatal stroke (ischemic and hemorrhagic) (Direct measurement)
Non-fatal stroke (ischemic and hemorrhagic) will be obtained through follow-up of subjects.
Time frame: 12 months, 36 months, 60 months
CRP and POCE
Prognostic value of CRP on POCE
Time frame: 12 months, 36 months, 60 months
Plan to share: No
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Jan 2032, 79 months after the start.
Of 134 non-industry interventional studies with no phase under ST Elevation Myocardial Infarction, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's planned 79 months is above that.
Counting every sponsor, half of 143 studies reached it within 38 months; a quarter within 19 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ST Elevation Myocardial Infarction →
Second Affiliated Hospital, Zhejiang University, School of Medicine →